This bill would punish sham FDA petitions that slow approval of generic drugs and biosimilars. The Federal Trade Commission could sue and seek large fines when petitions are used mainly to block competition.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Stop STALLING Act is a Senate bill waiting for floor action. The latest recorded action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Latest action on S. 1095: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Who this affects: This bill mainly affects drug companies that use FDA petitions during generic drug or biosimilar approval. It also affects generic and biosimilar makers waiting to compete. Patients, insurers, employers, and government health programs could feel the effect if faster competition changes drug prices or availability, though the bill does not estimate that effect.
Why this matters: This bill matters because slow drug competition can keep cheaper options off the market longer. It tries to stop companies from using weak FDA petitions as a delay tool. If it works, generic drugs and biosimilars may reach patients sooner. But the bill also raises the stakes for petition filers, so some may worry it could chill real safety complaints.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
